Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 13,082 as of Monday, Nov. 5, 2012, 1:34 PM ET. The NYSE advances/declines ratio sits at 1,351 issues advancing vs. 1,574 declining with 129 unchanged. The Health Services industry currently sits up 0.2% versus the S&P 500, which is down 0.1%. TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today: 4. Humana ( HUM) is one of the companies pushing the Health Services industry lower today. As of noon trading, Humana is down $0.44 (-0.6%) to $74.77 on heavy volume Thus far, 2.7 million shares of Humana exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $72.88-$76.77 after having opened the day at $76.72 as compared to the previous trading day's close of $75.21. Humana Inc. operates as a health care company that offers a range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. Humana has a market cap of $12.3 billion and is part of the health care sector. The company has a P/E ratio of 10.1, below the S&P 500 P/E ratio of 17.7. Shares are down 13.3% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Humana a buy, no analysts rate it a sell, and 8 rate it a hold. TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.